|Bid||11.93 x 800|
|Ask||11.94 x 1300|
|Day's range||11.92 - 12.36|
|52-week range||11.58 - 29.65|
|Beta (5Y monthly)||1.31|
|PE ratio (TTM)||67.63|
|Earnings date||10 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||27.63|
A look at the shareholders of Cara Therapeutics, Inc. ( NASDAQ:CARA ) can tell us which group is most powerful...
The future of this troubled clinical-stage biotech rests on a single drug candidate that management hopes will treat an extremely common condition.
With the clinical trial process in the rearview mirror, a lot of the risks associated with development are in the past, leaving "only" the risks of competing profitably. Such is the situation of Cara Therapeutics (NASDAQ: CARA), which is developing a drug called Korsuva to treat pruritus. You've probably experienced pruritus (at least to a small degree) before, because it's the sensation of itchiness.